Clinical practice and prospects of septal myectomy in the treatment of hypertrophic cardiomyopathy
10.3760/cma.j.cn112139-20250531-00283
- VernacularTitle:肥厚型心肌病室间隔切除术的临床实践与展望
- Author:
Tao LU
1
;
Shuiyun WANG
Author Information
1. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院成人外科中心，北京 100037
- Publication Type:Journal Article
- Keywords:
Cardiomyopathy,hypertrophic;
Surgical procedures, operative;
Septal myectomy;
Mitral valve;
Minimally invasive therapy
- From:
Chinese Journal of Surgery
2025;63(12):1097-1103
- CountryChina
- Language:Chinese
-
Abstract:
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder primarily characterized by left ventricular outflow tract obstruction (LVOTO), and septal myectomy remains the gold standard for treating this disease. A thorough understanding of the pathophysiological mechanisms underlying LVOTO can help surgeons refine their techniques for septal muscle resection and mitral valve management, ensuring complete relief of obstruction. Sixty years of accumulated data and experience have demonstrated that surgery not only significantly alleviates symptoms but also improves cardiac function and long-term prognosis. With advancements in minimally invasive surgical techniques, thoracoscopic and small-incision approaches have become valuable complements to the surgical treatment of obstructive HCM. Additionally, alcohol septal ablation, percutaneous radiofrequency ablation, and novel targeted pharmacotherapies provide more options for disease management. Overall, septal myectomy remains the cornerstone of HCM treatment, while future developments in personalized treatment strategies and minimally invasive techniques are expected to further enhance therapeutic outcomes and patient quality of life.
